Cedric Francois, Chief Executive Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 30,000 shares at $82.02 ($2.5M) on 2023-04-18, disclosed to the SEC on 2023-04-20.
Scheduled sale ($2.5M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| APLS | SELL | 2026-01-15 | $226K | — | Filing → |
| APLS | SELL | 2025-08-29 | $12.7M | — | Filing → |
| APLS | SELL | 2025-07-18 | $797K | — | Filing → |